Proteomics-Based Identification of Differentially-Expressed Proteins Including Galectin-1 in the Blood Plasma of Type 2 Diabetic Patients

2009 ◽  
Vol 8 (3) ◽  
pp. 1255-1262 ◽  
Author(s):  
XiaoJun Liu ◽  
QiPing Feng ◽  
Yong Chen ◽  
Jin Zuo ◽  
Nishith Gupta ◽  
...  
Keyword(s):  
Blood Plasma ◽  
Differentially Expressed ◽  
Diabetic Patients ◽  
Differentially Expressed Proteins ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

scholarly journals Differential Proteome Profiling Using iTRAQ in Microalbuminuric and Normoalbuminuric Type 2 Diabetic Patients

2012 ◽  
Vol 2012 ◽  
pp. 1-31 ◽  
Author(s):  
Jonghwa Jin ◽  
Yun Hyi Ku ◽  
Yikwon Kim ◽  
Yeonjung Kim ◽  
Kyunggon Kim ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Multiple Reaction Monitoring ◽  
Absolute Quantification ◽  
Differentially Expressed ◽  
Diabetic Patients ◽  
Differentially Expressed Proteins ◽  
Type 2 Diabetic Patients ◽  
Stage Renal Disease ◽  
Type 2 Diabetic

Diabetic nephropathy (DN) is a long-term complication of diabetes mellitus that leads to end-stage renal disease. Microalbuminuria is used for the early detection of diabetic renal damage, but such levels do not reflect the state of incipient DN precisely in type 2 diabetic patients because microalbuminuria develops in other diseases, necessitating more accurate biomarkers that detect incipient DN. Isobaric tags for relative and absolute quantification (iTRAQ) were used to identify urinary proteins that were differentially excreted in normoalbuminuric and microalbuminuric patients with type 2 diabetes where 710 and 196 proteins were identified and quantified, respectively. Some candidates were confirmed by 2-DE analysis, or validated by Western blot and multiple reaction monitoring (MRM). Specifically, some differentially expressed proteins were verified by MRM in urine from normoalbuminuric and microalbuminuric patients with type 2 diabetes, wherein alpha-1-antitrypsin, alpha-1-acid glycoprotein 1, and prostate stem cell antigen had excellent AUC values (0.849, 0.873, and 0.825, resp.). Moreover, we performed a multiplex assay using these biomarker candidates, resulting in a merged AUC value of 0.921. Although the differentially expressed proteins in this iTRAQ study require further validation in larger and categorized sample groups, they constitute baseline data on preliminary biomarker candidates that can be used to discover novel biomarkers for incipient DN.

scholarly journals Identification of Novel Genes Differentially Expressed in Omental Fat of Obese Subjects and Obese Type 2 Diabetic Patients

Diabetes ◽  
2001 ◽  
Vol 50 (12) ◽  
pp. 2822-2830 ◽  
Author(s):  
H. Corominola ◽  
L. J. Conner ◽  
L. S. Beavers ◽  
R. A. Gadski ◽  
D. Johnson ◽  
...  
Keyword(s):  
Differentially Expressed ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Novel Genes ◽  
Obese Subjects ◽  
Omental Fat ◽  
Type 2 Diabetic

scholarly journals Genes for systemic vascular complications are differentially expressed in the livers of Type 2 diabetic patients

Diabetologia ◽  
2004 ◽  
Vol 47 (4) ◽  
pp. 638-647 ◽  
Author(s):  
T. Takamura ◽  
M. Sakurai ◽  
T. Ota ◽  
H. Ando ◽  
S. Kaneko ◽  
...  
Keyword(s):  
Vascular Complications ◽  
Differentially Expressed ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: A role of plasma esterases

2006 ◽  
Vol 1760 (2) ◽  
pp. 207-215 ◽  
Author(s):  
Peter Grešner ◽  
Martin Dolník ◽  
Iveta Waczulíková ◽  
Maria Bryszewska ◽  
Libuša Šikurová ◽  
...  
Keyword(s):  
Acetylsalicylic Acid ◽  
Blood Plasma ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Hydrolysis Of ◽  
Type 2 Diabetic

scholarly journals VISFATIN LEVEL DISTURBANCES IN PERIPHERAL BLOOD OF PATIENTS WITH DIABETIC NEPHROPATHY

2014 ◽  
pp. 25-30
Author(s):  
I.I. Topchii ◽  
P.S. Semenovykh ◽  
V.YU. Galchinskaya ◽  
N.V. Yefimova
Keyword(s):  
Diabetic Nephropathy ◽  
Blood Plasma ◽  
Peripheral Blood ◽  
Control Group ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Visfatin Level ◽  
Type 2 Diabetic ◽  
In Blood Plasma

 Introduction. Recent studies suggest that visfatin participates in pathogenesis of vascular diabetic complications, in particular diabetic nephropathy (DN). The aim of the present research - definition of visfatin level in peripheral blood of type 2 diabetic patients taking to account renal function disturbances and body mass index (BMI). Materials and methods. 94 type 2 diabetic patients with different stages of DN and 10 healthy subjects (control group) were observed. Visfatin concentration in blood plasma was determined using immunoassay kit. Results. An essential increase of visfatin level in blood plasma took place already in initial stages of the DN. Progressing of the disease was accompanied by more expressed growth of visfatin concentration. In patients with high BMI substantial increase of visfatin level when compared with those with normal IMT was determined. We established strong correlations between visfatin concentrations, urinary albumin levels and blood creatinine concentrations and negative correlations with glomerular filtration rate. Conclusions: Our findings testify that visfatin level displays a functional kidney state and may be used as addition to traditional methods of patients examination.

Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial

2020 ◽  
pp. 1-10
Author(s):  
Giuseppe Derosa ◽  
Angela D’Angelo ◽  
Chiara Martinotti ◽  
Maria Chiara Valentino ◽  
Sergio Di Matteo ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Metabolic Control ◽  
Vitamin D3 ◽  
Therapy Group ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Abstract. Background: to evaluate the effects of Vitamin D3 on glyco-metabolic control in type 2 diabetic patients with Vitamin D deficiency. Methods: one hundred and seventeen patients were randomized to placebo and 122 patients to Vitamin D3. We evaluated anthropometric parameters, glyco-metabolic control, and parathormone (PTH) value at baseline, after 3, and 6 months. Results: a significant reduction of fasting, and post-prandial glucose was recorded in Vitamin D3 group after 6 months. A significant HbA1c decrease was observed in Vitamin D3 (from 7.6% or 60 mmol/mol to 7.1% or 54 mmol) at 6 months compared to baseline, and to placebo (p < 0.05 for both). At the end of the study period, we noticed a change in the amount in doses of oral or subcutaneous hypoglycemic agents and insulin, respectively. The use of metformin, acarbose, and pioglitazone was significantly lower (p = 0.037, p = 0.048, and p = 0.042, respectively) than at the beginning of the study in the Vitamin D3 therapy group. The units of Lispro, Aspart, and Glargine insulin were lower in the Vitamin D3 group at the end of the study (p = 0.031, p = 0.037, and p = 0.035, respectively) than in the placebo group. Conclusions: in type 2 diabetic patients with Vitamin D deficiency, the restoration of value in the Vitamin D standard has led not only to an improvement in the glyco-metabolic compensation, but also to a reduced posology of some oral hypoglycemic agents and some types of insulin used.

Sign in / Sign up

Export Citation Format

Share Document